maintain market perform rate share
follow review result outlook
guidanc potenti declin revenu flat ep
growth aggress share repurchas repatri ex-u cash
see attract organ growth opportun within
particular
aimovig appear attract encourag pipelin
progress howev risk core franchis product appear signific
could leav share rang bound
report oper result yesterday
provid guidanc ep
consensu revenu non-gaap ep
non-gaap tax rate guidanc includ
revenu non-gaap ep non-
tax rate capital-expenditure approx
decreas ep estim
tax reform note cash ex-u
compani sever initi plan one acceler share
repurchas addit author board
remain full could
purchas invest amgen ventur
amount total invest sinc addit
plan increas invest infrastructur note
build next-gen biolog manufactur plant part
capital-expenditure invest year
overal revenu line reflect increas
demand new product offset declin older product
highlight yoy qoq growth prolia achiev
fy sale driven new patient
repeat patient visit yoy qoq growth kyproli
achiev fy sale driven
continu intern growth updat surviv either
includ expect includ product label see
kyproli regimen new standard relapsed/refractori
multipl myeloma xgeva sale
yoy new label mm note
new import larg growth opportun sensipar
neulasta sale flat onpro account
neulasta unit sold ahead potenti biosimilar competit
product note broad ep guidanc
continu slow eros net sell price expect
continu esa franchis also due reduct
unit net sell price plan
increas competit includ potenti biosimilar epogen
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
repatha sale increas qoq yoy sale driven higher demand revis
label allow promot cardiac outcom note first week
promot new label new prescript increas
move pipelin highlight sever program fit vision volume-bas product
growth includ aimovig partner nv migrain pdufa date approv
aimovig would first calcitonin gene receptor peptid antagonist prevent migrain
antagonist target receptor also note tezepelumab partner azn
recent began phase patient trial sever uncontrol asthma note
tezepelumab target thymic stromal lymphopoietin upstream regul inflamm could
broad util inflammatori diseas chronic obstruct pulmonari diseas atop
oncolog remain focu compani note addit expand bite
cell engag platform compani file first ind chimer antigen receptor cell product
emerg gild/kit collabor bite develop includ half-lif
extend compound bite target cell matur antigen antibodi drug
conjug also highlight bispecif antibodi direct target jnj
price target nc
arriv price target appli multipl ep estim
risk includ greater expect eros base biolog busi competit kyproli
gener velcad emerg myeloma treatment failur gain approv proprietari
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
